Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Key ADC Studies at ASCO 2024

August 12th 2024

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

Rhenium Obisbemeda Demonstrates Safety and Feasibility in Leptomeningeal Metastases

August 12th 2024

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

Dr Aggarwal on the Rationale For Evaluating CAN-2409 in NSCLC

August 12th 2024

Charu Aggarwal, MD, MPH, FASCO, discusses the evaluation of CAN-2409, valacyclovir, and continued immune checkpoint inhibitors in NSCLC.

T-Cell Therapy Deltacel Elicits Early Safety and Efficacy in NSCLC

August 9th 2024

Deltacel generated early signals of clinical efficacy in patients with metastatic non–small cell lung cancer who have not responded to standard therapies.

Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC

August 8th 2024

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Merck Discontinues KeyVibe-008 Trial of Vibostolimab/Pembrolizumab Plus Chemo in ES-SCLC

August 8th 2024

The KeyVibe-008 trial evaluating vibostolimab, pembrolizumab, and chemotherapy in extensive-stage small cell lung cancer has been discontinued.

Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities

August 7th 2024

Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.

Paramountcy of Molecular Testing Is Increasing in Early-Stage NSCLC

August 7th 2024

Fred R. Hirsch, MD, PhD, discusses the role of molecular testing in non–small cell lung cancer.

Selpercatinib Maintains PFS Benefit vs Chemotherapy in East Asian Patients With Untreated RET+ NSCLC

August 7th 2024

East Asian patients with RET fusion-positive NSCLC experienced a PFS benefit when treated with selpercatinib vs chemotherapy with/without pembrolizumab.

Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

August 6th 2024

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Dr Ramsey on Signs and Symptoms of Pneumonitis in Locally Advanced NSCLC

August 6th 2024

Meghan Ramsey, MD, discusses signs and symptoms of pneumonitis in locally advanced non–small cell lung cancer.

Dr Parikh on the Impact of the ADAURA and ALINA Trials on Early-Stage NSCLC Management

August 5th 2024

Kaushal Parikh, MBBS, discusses how data from the ADAURA and ALINA trials have advanced the management of early-stage non–small cell lung cancer.

Dr Bazhenova on Improving Biomarker Development in Lung Cancer

August 5th 2024

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Challenges and Learnings from EVOKE-01

August 5th 2024

Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.

Dr Florez on Addressing Key Gaps in Lung Cancer Care

August 5th 2024

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Targeting of HER3: Insights from HERTHENA-Lung01

August 5th 2024

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.

LP-300 Plus Chemo Yields Early Efficacy Results in Never-Smokers With NSCLC

August 5th 2024

LP-300 plus pemetrexed/carboplatin exhibited disease control in never-smokers with advanced NSCLC following progression on prior TKI treatment.

PD-L1 Expression Remains Primary Guide for NSCLC Treatment Selection in the Absence of Targetable Mutations

August 5th 2024

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

Refining Adjuvant Immunotherapy Use Is a Crucial Focus in Early-Stage NSCLC

August 2nd 2024

Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.

Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC

August 2nd 2024

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.